Century Therapeutics (IPSC) Short-term Investments (2020 - 2026)

Century Therapeutics (IPSC) has reported Short-term Investments for 7 consecutive years, with $83.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Short-term Investments fell 26.05% year-over-year to $83.8 million; the TTM figure through Mar 2026 stood at $83.8 million (down 26.05% YoY), while the FY2025 annual figure was $55.3 million, down 57.77% from the prior year.
• Short-term Investments climbed to $83.8 million in Q1 2026 per IPSC's latest filing, from $55.3 million in the prior quarter.
• Across five years, Short-term Investments topped out at $266.0 million in Q2 2022 and bottomed at $55.3 million in Q4 2025.
• Historically, Short-term Investments has averaged $145.8 million across 5 years, with a median of $130.9 million in 2024.
• Annual changes were most pronounced in 2022 — Short-term Investments jumped 112.28% — and 2023, when it slumped 65.43%.
• Century Therapeutics' Short-term Investments stood at $231.2 million in 2022, then slumped by 45.76% to $125.4 million in 2023, then advanced by 4.34% to $130.9 million in 2024, then plunged by 57.77% to $55.3 million in 2025, then soared by 51.56% to $83.8 million in 2026.
• Business Quant data shows IPSC's Short-term Investments at $83.8 million in Q1 2026, $55.3 million in Q4 2025, and $77.2 million in Q3 2025.